How Bioxyne’s €3.2M German Deal Fuels Record Revenue Surge
Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.
- Q4 FY25 revenue hits $9.5 million, up 204% year-on-year
- FY25 unaudited revenue of $29.3 million exceeds guidance by $1.3 million
- Positive operating cash flow of $1.5 million in Q4
- €3.2 million manufacturing and supply contract secured in Germany
- Plans to expand manufacturing capacity and launch medicinal cannabis in Europe
Record Revenue Growth
Bioxyne Limited (ASX – BXN) has delivered an exceptional performance in the fourth quarter of FY25, posting record revenue of $9.5 million. This represents a remarkable 204% increase compared to the same quarter last year and a 33% rise from the previous quarter. The company’s unaudited full-year revenue reached $29.3 million, surpassing its guidance of $28 million by $1.3 million, signaling robust demand and operational execution.
Strong Cash Flow and Operational Investment
Alongside revenue growth, Bioxyne generated positive operating cash flow of $1.5 million in Q4, marking the fourth consecutive quarter of cash flow positivity. The company invested $0.3 million in capital expenditure during the quarter, focusing on expanding manufacturing capacity through upgrades to plant, equipment, and security infrastructure. These investments underpin Bioxyne’s readiness to meet increasing market demand.
Strategic European Expansion
A significant highlight of the quarter was Bioxyne’s entry into the German market via a €3.2 million (approximately A$5.8 million) manufacturing and supply agreement with Farmakem and Adrex. This contract not only strengthens Bioxyne’s foothold in Europe but also sets the stage for further expansion across the UK and European markets. Initial product supply will be managed from Australia while the company develops local manufacturing operations in the EU and UK, which remain at an early stage.
Growth Drivers and Future Outlook
The company’s subsidiary, Breathe Life Sciences (BLS), continues to be the primary revenue driver, leveraging its position as Australia’s leading manufacturer and wholesaler of novel medicines, including cannabis, MDMA, and psilocybin. Bioxyne is actively pursuing EU GMP certification in Czechia to facilitate distribution across Europe and plans to launch medicinal cannabis products in the UK and European markets through local partnerships.
CEO Sam Watson expressed optimism about the company’s trajectory, highlighting the operational readiness of new manufacturing facilities and the potential for multiple additional contracts in Australia and overseas. The Board is expected to provide FY26 guidance alongside the audited FY25 results next month, with expectations to substantially exceed FY25 revenue performance.
Bottom Line?
Bioxyne’s strong finish to FY25 and strategic European entry position it for accelerated growth, but execution of EU manufacturing and contract expansion will be critical to watch.
Questions in the middle?
- How quickly can Bioxyne establish local manufacturing operations in the EU and UK?
- What additional contracts are in negotiation, and how might they impact FY26 revenue?
- When will Bioxyne achieve EU GMP certification, and what regulatory hurdles remain?